All In MedTech

FDA Clearance Tracker · P160041

COBAS CMV

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jun 1, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 1, 2017

Approved (reclassified)

Time to decision

253 days

Received Sep 21, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P160041
Device name
COBAS CMV
Applicant location
Pleasanton, CA
Received
Sep 21, 2016
Decided
Jun 1, 2017
Decision
Approved (reclassified)
Supplements
46 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3180

Every decision under product code PAB

FDA's approval statement

As written in FDA's record.

Approval of the cobas CMV test - This device is indicated for:cobas® CMV is an in vitro nucleic acid amplification test for the quantitation of cytomegalovirus (CMV) DNA in human EDTA plasma. cobas® CMV is intended for use as an aid in the management of CMV in solid organ transplant patients and in hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from cobas® CMV must be interpreted within the context of all relevant clinical and laboratory findings. cobas® CMV is not intended for use as a screening test for blood or blood products.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Roche Molecular Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.